2. Search Result
Search Result
Results for "

neurogenic pain

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110220
    CIM0216
    3 Publications Verification

    		 TRP Channel Neurological Disease
    CIM0216, a synthetic TRPM3 ligand, acts as a potent and selective agonist of TRPM3. CIM0216 exhibits selectivity for TRPM3 over TRPM1, TRPM2 and TRPM4-8. CIM0216 acts in a TRPM3-dependent manner to induce pain and evoke neuropeptide release from sensory nerve terminals in vitro. CIM0216 is a powerful tool for studies of the physiological functions of TRPM3, and can be used for neurogenic inflammation research .
    CIM0216
  • HY-108483
    RP 67580

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation .
    RP 67580
  • HY-14406A
    L-733060 hydrochloride
    1 Publications Verification

    		 Neurokinin Receptor Neurological Disease Cancer
    L-733060 hydrochloride is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 hydrochloride mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 hydrochloride blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 hydrochloride reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 hydrochloride can be used for the study of chronic orofacial pain .
    L-733060 hydrochloride
  • HY-19665
    Lanepitant

    LY303870

    		 Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Lanepitant (LY303870) is a selective neurokinin-1 (NK-1) receptor antagonist. Lanepitant blocks neurogenic inflammation and pain transmission by preventing the binding of substance P to NK-1 receptors on both neuronal and non-neuronal tissues. Lanepitant can be used to study osteoarthritis .
    Lanepitant
  • HY-137090
    BP 2-94

    BP 2.94

    		 Histamine Receptor Neurological Disease
    BP 2-94 (BP 2.94) is an orally active and highly selective prodrug targeting the histamine H3 receptor. BP 2-94 exerts anti-inflammatory, analgesic and antinociceptive effects by inhibiting histamine release and modulating neurogenic inflammation. BP 2-94 is promising for research of asthma, migraines, and inflammatory pain-related disorders .
    BP 2-94
  • HY-14406
    L-733060

    		Neurokinin Receptor Neurological Disease Cancer
    L-733060 is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 can be used for the study of chronic orofacial pain .
    L-733060
  • HY-17012
    Dapitant

    RPR 100893

    		 Neurokinin Receptor Inflammation/Immunology
    Dapitant (RPR 100893) is a non-peptide Substance P antagonist with high affinity for the human NK1 receptor. It belongs to the 7,7,4-trimethylperhydroisoindole class of compounds. Dapitant inhibits the binding of Substance P to NK1 receptors, thereby blocking its neurokinin-mediated effects. This novel antagonist represents a potential therapeutic option for conditions involving Substance P, such as neurogenic inflammation and pain modulation .
    Dapitant
  • HY-174848
    PQM-244

    		TRP Channel Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    PQM-244 (Compound 5c) is an orally active and multi-target modulator of TRPV1 and CB1 and CB2 receptors. PQM-244 has significant peripheral antinociceptive effects on both neurogenic and inflammatory phases. PQM-244 also has potential antioxidant activity with an IC50  of  14.15 µM for radical scavenging DPPH. PQM-244 can be used for chronic pain and inflammatory disease research, such as diabetes, atherosclerosis and Alzheimer’s disease .
    PQM-244
  • HY-N19281
    Puberulin

    		Drug Derivative Neurological Disease
    Puberulin is a coumarin compound and an orally effective analgesic. Puberulin is present in Choisya ternata var. Sundance. Puberulin exerts analgesic activity against chemical and heat-induced pain agents in mouse models, and this activity does not involve opioid receptors or muscarinic receptors. Puberulin can be used in the research of neuropathic pain .
    Puberulin
  • HY-WAA0304
    Agmatine

    		5-HT Receptor Adrenergic Receptor Imidazoline Receptor Neurological Disease
    Agmatine is an orally active analgesic that can cross the blood-brain barrier. Agmatine targets the 5-HT2A receptor, 5-HT3 receptor, α2-adrenergic receptor, and I1 imidazoline receptor. Agmatine produces dose-dependent analgesic effects in various pain models. Agmatine can be used in research related to visceral pain, neuropathic pain, and inflammatory pain .
    Agmatine
  • HY-183857
    DD-161515

    		TRP Channel Neurological Disease
    DD-161515 is a TRPV1/VR1 inhibitor with an IC50 of 0.7 μM in rats. DD-161515 binds to an allosteric site of TRPV1 distinct from that of capsaicin, blocks channel opening, inhibits receptor-mediated calcium ion influx, reduces the excitability of peripheral sensory nerve fibers, and thereby inhibits nociception induced by heat and transmission of chemically induced pain signals. DD-161515 can be used in studies related to inflammatory pain .
    DD-161515
  • HY-179684
    PCC0105005

    		CGRP Receptor 5-HT Receptor ERK Epigenetic Reader Domain Neurological Disease
    PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine .
    PCC0105005

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: